Details for Patent: 11,229,647
✉ Email this page to a colleague
Which drugs does patent 11,229,647 protect, and when does it expire?
Patent 11,229,647 protects LIVMARLI and is included in two NDAs.
This patent has fifty-two patent family members in sixteen countries.
Summary for Patent: 11,229,647
| Title: | Methods for treating cholestasis |
| Abstract: | Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg/kg/day. |
| Inventor(s): | Thomas JAECKLIN, Alejandro Dorenbaum |
| Assignee: | Mirum Pharmaceuticals Inc |
| Application Number: | US16/994,368 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,229,647 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; |
| Patent landscape, scope, and claims: |
More… ↓ |
Drugs Protected by US Patent 11,229,647
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirum | LIVMARLI | maralixibat chloride | SOLUTION;ORAL | 214662-001 | Sep 29, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS) | ⤷ Start Trial | ||||
| Mirum | LIVMARLI | maralixibat chloride | SOLUTION;ORAL | 214662-001 | Sep 29, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH ALAGILLE SYNDROME (ALGS) | ⤷ Start Trial | ||||
| Mirum | LIVMARLI | maralixibat chloride | TABLET;ORAL | 219485-001 | Apr 10, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS) WHO WEIGH 25 KILOGRAMS AND ABOVE | ⤷ Start Trial | ||||
| Mirum | LIVMARLI | maralixibat chloride | TABLET;ORAL | 219485-002 | Apr 10, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS) WHO WEIGH 25 KILOGRAMS AND ABOVE | ⤷ Start Trial | ||||
| Mirum | LIVMARLI | maralixibat chloride | TABLET;ORAL | 219485-003 | Apr 10, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS) WHO WEIGH 25 KILOGRAMS AND ABOVE | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,229,647
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2020221239 | ⤷ Start Trial | |||
| Australia | 2020221834 | ⤷ Start Trial | |||
| Australia | 2020223022 | ⤷ Start Trial | |||
| Australia | 2026203990 | ⤷ Start Trial | |||
| Brazil | 112021015799 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
